Erbitux 100mg 1vial 20ml 

Merck 

475.00 

465.69 

365.38 

Active substance: Cetuximab 100 mg; Excipients: Sodium dihydrogen phosphate dihydrate 20 mg, disodium phosphate dihydrate 66 mg, sodium chloride 424 mg, water for injections to 50 mL 

In combination with irinotecan for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. 

Erbitux is contraindicated in patients with known severe (grade 3 or 4) hypersensitivity reactions to cetuximab; Pregnancy and lactation. For additional contraindications on irinotecan, refer to the product information for this medicinal product. 

Erbitux must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products. Ciose monitoring is required during the infusion and for at least 1 hour after the end of the infusion. Availability of resuscitation equipment must be ensured. Prior to the first infusion, patients must receive premedication with an antihistamine. Similar premedication is recommended prior to all subsequent infusions. Erbitux is administered once a week. The initial dose is 400 mg cetuximab per m2 body surface area. The subsequent weekly doses are each 250 mg/m2. For the dosage of concomitant irinotecan, refer to the product information for this medicinal product. Irinotecan must not be administered earlier than 1 hour after the end of the cetuximab infusion. It is recommended that cetuximab treatment be continued until progression of the underlying disease. Administration: Erbitux is administered intravenously via in-line filtration with a gravity drip, an infusion pump, or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes. For the subsequent weekly maintenance doses, the recommended infusion period is 60 minutes. The maximum infusion rate must not exceed 5 mL/min.